Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT05172284
Starting soon Observational

Registry and Monitoring of ImmuNe-mediated Inflammatory Diseases

NCT05172284 · tracked via the Priya Life Science Italy tracker
Sponsor
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Phase
Observational
Started
2022-02
Last updated
2022-01-11

Condition(s) studied

ImmuNe-Mediated Inflammatory Diseases

Investigational drug(s) / intervention(s)

Questionnaires

Questionnaires: This is a collection of data from normal clinical routine: patients will be asked to record the assessments they undergo during their course of treatment, without changing clinical practice in any way. Data inherent to the following procedures will be collected: examinations, laboratory tests, imaging tests, questionnaires and rating scales.

Study summary

Formation of a registry of IMID patients to assess the evolution of resistance to conventional and target therapies. This aim is achieved by evaluating the achievement of PASI 50 and PASI 75 scores at week 16 from the start of treatment.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with a diagnosis of IMID. * Patients of any age, including minors. * Patients treated with approved medications for the condition in question and/or phototherapy. * Patients who agree to sign informed consent. Exclusion Criteria: * Patients without a diagnosis of IMID. * Patients who do not consent to sign informed consent.

Primary outcome measure(s)

  • Registry of ImmuNe-mediated inflammatory Diseases (IMIDs) — 15 years
    Formation of a registry of IMID patients to assess the evolution of resistance to conventional and target therapies.

Trial sites (1)

FacilityCityRegionStatus
IRCCS Istituto Ortopedico Galeazzi Milan Italy

More I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio trials in Italy

Metabolic Profile of Bone in Professional Athletes Recruiting
Extracellular Vesicles in Fibrin Gel for Cartilage Repair Recruiting
ACL Reconstruction in Patients Aged 50 Years and Older Active, not recruiting
Evaluation of Limb Function and Perception in Rehabilitation After Traumatic Wrist Fracture Surgery Starting soon
The Influence of Perioperative Strategies on the Extent of in Orthopaedic Prosthetic Surgery Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05172284 on ClinicalTrials.gov ↗ ← All trials in Italy